• Home
  • News & Events
    • News Releases
    • Events & Presentations
    • Publications
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Governance Documents
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Annual Report and Proxy
    • Special Meeting Proxy
  • Stock Information
  • Resources
    • Email Alerts
    • Contact

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

Sep 22, 2025 | Press Releases

CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for...

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

Jul 16, 2025 | Press Releases

CINCINNATI, July 16, 2025 — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development and commercialization of...

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

Jun 16, 2025 | Press Releases

CINCINNATI, Ohio, June 16, 2025 — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s...

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

Jun 11, 2025 | Press Releases

CINCINNATI, Ohio, June 11, 2025 — Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s...

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

May 22, 2025 | Press Releases

Cincinnati, OH, May 22, 2025 — Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on May 20, 2025 indicating that the Company’s failure to...

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

Apr 30, 2025 | Press Releases

Cincinnati, OH, April 30, 2025 — Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on April 24, 2025 indicating that the Company’s failure to...
« Older Entries
Next Entries »

Recent Posts

  • Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement
  • Onconetix Announces Reverse Stock Split
  • Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition
  • CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
  • Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Recent Comments

No comments to show.

Stay up to date

Keep informed on investor news & updates

© 2026 Onconetix